CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-09). The draft was written by AI, all 3 cited sources were opened and checked for existence, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 160 · Search date 2026-07-09 · Methodology v0.6

Phosphatidylcholine/lecithin,
does it really help with Cognition and liver?

30-Second Summary
D
Evidence Grade D · 30 · Safety acceptable
The cognition-improvement claim was not supported in clinical trials
What the
research shows
For the cognition-improvement claim of lecithin/phosphatidylcholine, clear clinical cognitive benefit was not confirmed in the 2003 Cochrane review of 12 RCTs (Alzheimer disease, Parkinson dementia, and self-reported memory problems). However, because this is not primarily a harm-based judgment, it is D rather than F, meaning negative/insufficient for cognitive efficacy. Deficiency and correction of TPN-related fatty liver are separate nutritional contexts.
What the
ads claim
Advertisements combine 'brain cell membrane,' 'memory,' 'focus,' 'liver detox,' 'fatty liver,' and 'choline supply.' RCT evidence for cognition is negative, and liver claims need to distinguish deficiency correction from general supplementation.
*

Useful facts when choosing a product

  • Lecithin is not only phosphatidylcholine but a mixture of several phospholipids.
  • The actual choline amount provided by a product differs from the number of grams of lecithin.
  • High-dose choline is associated with discussions of fishy body odor, gastrointestinal symptoms, hypotension, and TMAO.
  • Soy lecithin contains little allergenic protein, but sensitive people should check source labeling.
Gap Measurement · Verdict 160 · D 30
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Higgins/Flicker 2003 Cochrane review examined 12 RCTs using lecithin in Alzheimer disease, Parkinson dementia, and self-reported memory problems and did not confirm clear clinical cognitive benefit. Earlier large/multicenter lecithin studies in Alzheimer disease also did not show consistent cognitive improvement compared with placebo. For the liver, studies show that choline deficiency can be related to fatty liver in long-term TPN patients and can be reversed with choline administration, but this is evidence for deficiency treatment, not for general health-functional supplements.

02

Why this is classified as D (30)

For the representative cognition claim, the Cochrane review of 12 RCTs did not find clear clinical benefit. However, this is not a harm-centered judgment, and because there is a separate nutritional context of deficiency and TPN-related fatty liver correction, the grade is not F but D with 30 points.

Counterpoint. Choline nutritional status can matter in low-choline diets, TPN, and specific deficiency-risk groups. This judgment targets cognition and liver efficacy advertising for lecithin/PC supplements in non-deficient adults.

Rejudgment record. Final reassessment — No clinical cognitive benefit in 12 Cochrane RCTs; because the judgment is not harm-centered, D rather than F

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Higgins JPT, Flicker L 2003/2009Cochrane systematic reviewPublic/unknownCognitive function and clinical statusCould not confirm evidence of benefit of lecithin for dementia or cognitive impairment.Key
Study 2Randomized placebo-controlled trialsUnknownCognitive scoresNo consistent cognitive improvement compared with placebo.Key
Buchman AL et al. 1992/1995Deficiency/TPN-related clinical studyUnknownPlasma choline and liver fatShows an association between choline deficiency and fatty liver, but is not evidence of general supplement efficacy.Supportive
§

Receipt — 3 References

Every cited source was opened and checked against the live page on 2026-07-09.

Higgins JPT, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev. 2003;(3):CD001015. DOI: 10.1002/14651858.CD001015.
checked
Phosphatidylcholine/lecithin summary, including Cochrane conclusion on dementia trials. Wikipedia medical references.
checked
Buchman AL, et al. Choline deficiency and hepatic abnormalities in long-term parenteral nutrition patients. Gastroenterology/JPEN studies. 1992-1995.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-09 · Corrections: none

Cite this verdict

Phosphatidylcholine/lecithin x cognition and liver Evidence Grade D card
[Chamgap] Phosphatidylcholine/lecithin x cognition and liver — Evidence Grade D·30. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/cognition/phosphatidylcholine-lecithin-cognition-liver/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.